Unity Biotechnology, Inc. (UBX)
Automate Your Wheel Strategy on UBX
With Tiblio's Option Bot, you can configure your own wheel strategy including UBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol UBX
- Rev/Share 0.0
- Book/Share -0.0122
- PB -56.6201
- Debt/Equity -91.1073
- CurrentRatio 1.9465
- ROIC -1.3986
- MktCap 11841994.0
- FreeCF/Share -1.3063
- PFCF -0.5373
- PE -0.422
- Debt/Assets 0.6154
- DivYield 0
- ROE -2.7374
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | UBX | H.C. Wainwright | Buy | Neutral | -- | $2 | May 27, 2025 |
| Downgrade | UBX | Mizuho | Outperform | Neutral | $6 | $1 | May 16, 2025 |
| Initiation | UBX | Rodman & Renshaw | -- | Buy | -- | $8 | Aug. 22, 2024 |
News
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah.
Read More
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Negative
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
Read More
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Published: March 24, 2025 by: Benzinga
Sentiment: Negative
Unity Biotechnology, Inc. UBX stock plummeted on Monday after the company released results from its latest study.
Read More
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call …
Read More
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
Published: March 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here .
Read More
About Unity Biotechnology, Inc. (UBX)
- IPO Date 2018-05-03
- Website https://unitybiotechnology.com
- Industry Biotechnology
- CEO Dr. Anirvan Ghosh Ph.D.
- Employees 16